Comparative study of the sensitivities of cancer cells to doxorubicin, and relationships between the effect of the drug-efflux pump P-gp

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 12, 2014, Pages 1926-1935

  Kibria, Golam ^a   Hatakeyama, Hiroto ^a   Akiyama, Kosuke ^a   Hida, Kyoko ^a   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Cytotoxicity; Doxorubicin; Drug availability cell sensitivity correlation; Multi drug resistance; Pglycoprotein (P gp) dependence

Indexed keywords

DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; VERAPAMIL; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL CELL; ARTICLE; CANCER CELL DESTRUCTION; CANCER CELL LINE; CANCER RESISTANCE; CELL VIABILITY; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EC50; FEMALE; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; DRUG RESISTANCE; METABOLISM; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN; VERAPAMIL;

EID: 84919754484     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00529     Document Type: Article

References (57)

1. Malhotra V, Perry MC. Classical chemotherapy: mechanisms, toxicities and the therapeutic window. Cancer Biol. Ther., 2 (Suppl. 1), S2-S4 (2003).
2. Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Crit. Rev. Oncol. Hematol., 36, 193-207 (2000).
3. Goldie JH. Drug resistance in cancer: a perspective. Cancer Metastasis Rev., 20, 63-68 (2001).
4. O'Driscoll L, Clynes M. Biomarkers and multiple drug resistance in breast cancer. Curr. Cancer Drug Targets, 6, 365-384 (2006).
5. Kibria G, Hatakeyama H, Harashima H. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch. Pharm. Res., 37, 4-15 (2014).
6. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int., 5, 30 (2005).
7. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 56, 185-229 (2004).
8. Solomon R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin. Lymphoma Myeloma, 8, 21-32 (2008).
9. Ramu A, Fuks Z, Gatt S, Glaubiger D. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate. Cancer Res., 44, 144-148 (1984).
10. Young RC. Ovarian cancer treatment: progress or paralysis. Semin. Oncol., 11, 327-329 (1984).
11. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control., 10, 159-165 (2003).
12. Sarkadi B, Homolya L, Szakács G, Váradi A. Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system. Physiol. Rev., 86, 1179-1236 (2006).
13. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica, 38, 802-832 (2008).
14. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 42, 155-199 (1990).
15. Simpson WG. The calcium channel blocker verapamil and cancer chemotherapy. Cell Calcium, 6, 449-467 (1985).
16. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J. Biol. Chem., 262, 7884-7888 (1987).
17. Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res., 49, 5002-5006 (1989).
18. Muller C, Bailly JD, Goubin F, Laredo J, Jaffrézou JP, Bordier C, Laurent G. Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines. Int. J. Cancer, 56, 749-754 (1994).
19. Ohga N, Ishikawa S, Maishi N, Akiyama K, Hida Y, Kawamoto T, Sadamoto Y, Osawa T, Yamamoto K, Kondoh M, Ohmura H, Shinohara N, Nonomura K, Shindoh M, Hida K. Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors. Am. J. Pathol., 180, 1294-1307 (2012).
20. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells. Biomaterials, 34, 5617-5627 (2013).
21. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet, 352, 1691-1696 (1998).
22. Efferth T, Volm M. Protein expression profiles indicative for drug resistance of kidney carcinoma. Cancer Genomics Proteomics, 1, 17-22 (2004).
23. Staehler M, Rohrmann K, Bachmann A, Zaak D, Stief CG, Siebels M. Therapeutic approaches in metastatic renal cell carcinoma. BJU Int., 95, 1153-1161 (2005).
24. Soto-Vega E, Arroyo C, Richaud-Patin Y, García-Carrasco M, Vázquez-Lavista LG, Llorente L. P-glycoprotein activity in renal clear cell carcinoma. Urol. Oncol., 27, 363-366 (2009).
25. Oudard S, Levalois C, Andrieu JM, Bougaran J, Validire P, Thiounn N, Poupon MF, Fourme E, Chevillard S. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res., 22 (1A), 121-128 (2002).
26. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia, 3, 360-367 (2001).
27. Zhu H, Wang Z, Xu Q, Zhang Y, Zhai Y, Bai J, Liu M, Hui Z, Xu N. Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy. Cancer Biol. Ther., 13, 401-407 (2012).
28. Kausch I, Jiang H, Thode B, Doehn C, Krüger S, Jocham D. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma. Eur. Urol., 47, 703-709 (2005).
29. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res., 69, 9056-9064 (2009).
30. Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci., 97, 1198-1204 (2006).
31. Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am. J. Pathol., 180, 2490-2503 (2012).
32. Worm J, Kirkin AF, Dzhandzhugazyan KN, Guldberg P. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J. Biol. Chem., 276, 39990-40000 (2001).
33. Yen WC, Lamph WW. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol. Cancer Ther., 4, 824-834 (2005).
34. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J, Sugimoto Y. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol. Cancer Ther., 6, 2092-2102 (2007).
35. Milane L, Duan Z, Amiji M. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int., 11, 3 (2011).
36. Mladkova J, Sanda M, Matouskova E, Selicharova I. Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins. BMC Cancer, 10, 449 (2010).
37. Gautschi O, Tschopp S, Olie RA, Leech SH, Simões-Wüst AP, Ziegler A, Baumann B, Odermatt B, Hall J, Stahel RA, Zangemeister-Wittke U. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J. Natl. Cancer Inst., 93, 463-471 (2001).
38. Yu LJ, Matias J, Scudiero DA, Hite KM, Monks A, Sausville EA, Waxman DJ. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab. Dispos., 29, 304-312 (2001).
39. Kaye SB. Reversal of drug resistance in ovarian cancer: where do we go from here? J. Clin. Oncol., 26, 2616-2618 (2008).
40. Bradley G, Naik M, Ling V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res., 49, 2790-2796 (1989).
41. Bell DR, Gerlach JH, Kartner N, Buick RN, Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J. Clin. Oncol., 3, 311-315 (1985).
42. Zhu Z, Wang Y, Liu Z, Wang F, Zhao Q. Inhibitory effects of epigallocatechin-3-gallate on cell proliferation and the expression of HIF-1α and P-gp in the human pancreatic carcinoma cell line PANC-1. Oncol. Rep., 27, 1567-1572 (2012).
43. O'Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, O'Connor R, Clynes M, Crown J, Kennedy S. MDR1/P-glycoprotein and MRP-1 drug eflux pumps in pancreatic carcinoma. Anticancer Res., 27 (4B), 2115-2120 (2007).
44. Nguyen H, Zhang S, Morris ME. Effect of lavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharm. Sci., 92, 250-257 (2003).
45. Stein U, Fleuter C, Siegel F, Smith J, Kopacek A, Scudiero DA, Hite KM, Schlag PM, Shoemaker RH, Walther W. Impact of mutant β - catenin on ABCB1 expression and therapy response in colon cancer cells. Br. J. Cancer, 106, 1395-1405 (2012).
46. Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH. Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP. J. Natl. Cancer Inst., 89, 807-813 (1997).
47. Laurenc¸ot CM, Scheffer GL, Scheper RJ, Shoemaker RH. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int. J. Cancer, 72, 1021-1026 (1997).
48. Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J. Cell. Mol. Med., 11, 981-1011 (2007).
49. An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin. Drug Metab. Toxicol., 5, 1529-1542 (2009).
50. Schinkel AH, Jonker JW. Mammalian drug eflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev., 55, 3-29 (2003).
51. Sampath D, Discafani CM, Loganzo F, Beyer C, Liu H, Tan X, Musto S, Annable T, Gallagher P, Rios C, Greenberger LM. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol. Cancer Ther., 2, 873-884 (2003).
52. Jin Z, Gao F, Flagg T, Deng X. Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J. Biol. Chem., 279, 23837-23844 (2004).
53. Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Hermann E, Pliquett U, Neumann E, Zeuzem S. Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene, 22, 69-80 (2003).
54. Um JH, Kwon JK, Kang CD, Kim MJ, Ju DS, Bae JH, Kim DW, Chung BS, Kim SH. Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade. J. Pharmacol. Exp. Ther., 311, 1062-1070 (2004).
55. Li G, Chen X, Wang Q, Xu Z, Zhang W, Ye L. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance. J. Huazhong Univ. Sci. Technolog. Med. Sci., 27, 173-175 (2007).
56. De Rosa MF, Sillence D, Ackerley C, Lingwood C. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J. Biol. Chem., 279, 7867-7876 (2004).
57. Huffman KE, Corey DR. Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell line. Biochemistry, 44, 2253-2261 (2005).